Skip to content
Screener

Eikon Therapeutics, Inc. EIKN Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$350K+13.6%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$2.41M+22.0%
OnKure Therapeutics, Inc. logo
OnKure Therapeutics, Inc.OKUR
$409K-25.1%
Immunome logo
ImmunomeIMNM
$152K—
Erasca, Inc. logo
Erasca, Inc.ERAS
$5.25M+9.6%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$13M+8.3%

Other financials

Income statement

See full
Operating income-$87.3M-22.3%
Net income-$83.0M-21.6%
EPS (diluted)-$2.46+90.9%

Balance sheet

See full
Cash & equivalents$161.2M-21.2%
Total debt$254.8M—
Total equity$550.7M+186%
Total assets$850.8M—

Cash flow

See full
Operating cash flow-$89.8M-64.7%
CapEx$262.0K-98.8%
Free cash flow-$90.1M-17.1%

Valuation

See full
Market cap$502.95M-35.7%
Enterprise value$596.62M—

Returns & leverage

See full
Debt / equity0.5×—
Current ratio11.8×—

Where this comes from

Reported directly by Eikon Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The source filing: Eikon Therapeutics, Inc.’s 10-Q, filed May 11, 2026. Open the filing →

Filed
May 11, 2026, 4:13 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-216791

FAQ

What is Eikon Therapeutics, Inc.'s operating lease liabilities (current)?
Eikon Therapeutics, Inc. (EIKN) reported operating lease liabilities (current) of $9.74M in Q1 2026.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.

Ask your AI about Eikon Therapeutics, Inc.'s operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude